Pionyr Doses First Patient in Expansion Study

Pionyr Immunotherapeutics, a company founded by pathologist researcher Max Krummel from the University of California, is developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body's antitumor immunity by altering, or "tuning", immune cells within the tumor microenvironment. Pionyr announced today that the first patient has been dosed in Phase 1b expansion studies investigating PY314 in patients with solid tumors.

MORE